Physician profile
Daniel P Gray
NPI 1366435729
$1,100.62
in general payments reported to CMS, 2019-2025
11 companies · $439 in 2025
The $439 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $78.27 · 2022: $266 · 2023: $189 · 2024: $128 · 2025: $439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $756.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $756.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $242.71 | 2021-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $221.25 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $195.33 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Harrow Eye, LLC | $182.10 | 2024-2025 | Vevye |
| Bausch & Lomb Americas INC. | $106.40 | 2022-2024 | Xiidra, Vyzulta, Miebo |
| Abbvie INC. | $43.33 | 2022-2023 | |
| Alcon Vision LLC | $36.93 | 2022-2025 | Eysuvis |
| Omeros Corporation | $19.80 | 2021 | |
| Eyevance Pharmaceuticals LLC | $19.42 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $18.27 | 2021 | |
| Tearlab Corp | $15.08 | 2023 | Tearlab Osmolarity System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.